Penumbra (PEN)
Builds clot-removal, embolization, and vascular-access devices for neurovascular and peripheral procedures.
Something off on this page? Send us feedback.
Sells thrombectomy systems plus embolization and vascular-access devices to specialist physicians. Computer-assisted vacuum thrombectomy connects products used across stroke, pulmonary, venous, and peripheral arterial procedures, while the business operates as one segment and depends on regulatory clearance, manufacturing controls, and safe performance in acute care.
Develops, manufactures, and markets devices for removing blood clots and treating neurovascular and peripheral vascular disease. The single operating segment is organized around thrombectomy products and embolization and access products, with computer-assisted vacuum thrombectomy spanning stroke, pulmonary, venous, and peripheral arterial procedures.
Built through in-house engineering, testing, clinical, regulatory, and commercial capabilities, the portfolio grew from neurovascular access into a head-to-toe thrombectomy platform. Direct sales teams were established early in the United States and Europe, while specialist-physician relationships guide product development and adoption.
Product performance depends on regulatory clearance, manufacturing controls, and safe use in acute procedures. The JET 7 Xtra Flex catheter underwent a Class I recall, later terminated, and the agreed acquisition by Boston Scientific remains pending after shareholder approval.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 6, 2026 | Evercore ISI | Reiterate | Rating: —Target: $335 | Target: $320 |
| May 7, 2026 | Evercore ISI | Target | Target: $360 | Target: $335 |
| Feb 26, 2026 | UBS | Target | Target: $335 | Target: $374 |
| Feb 25, 2026 | Evercore ISI | Target | Target: $340 | Target: $360 |
| Jan 20, 2026 | RBC Capital | Downgrade | Target: $355 | Target: $374 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $658.8M · Total debt $212.7M · Total assets $1.97B · Shareholders' equity $1.53B
- Revenue
- $390.0M
- Operating income
- $41.0M
- Net income
- $34.8M
No dividends on record.
| Institutions | 87.64% | 34.52M shares | |
|---|---|---|---|
| 475 holders · as of Jun 30, 2026 | |||
| Insiders | 3.97% | 1.56M shares | |
| 12 holders · as of Sep 17, 2026 | |||
| Other | 8.39% | 3.30M shares | |
| remainder | |||
39.39M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 10.91% | 4.30M | as of Jun 30, 2026 |
HBK Investments L PInstitution | 4.67% | 1.84M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.34% | 1.71M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 4.23% | 1.67M | as of Jun 30, 2026 |
State Street CorpInstitution | 3.16% | 1.24M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 2, 2026 | Harpreet Grewal | director | −100 | $328.22 |
| Mar 2, 2026 | Maggie Yuen | officer: Chief Financial Officer | −2,432 | $342.30 |
| Jan 6, 2026 | Harpreet Grewal | director | −186 | $312.64 |
| Jan 2, 2026 | Thomas Wilder | director | −186 | $310.72 |
| Dec 11, 2025 | Arani Bose | director | −15,000 | $308.82 |
- Stryker
Broad overlap in stroke and peripheral mechanical thrombectomy
- Medtronic
Direct overlap in stroke thrombectomy, embolization, and access
- Boston Scientific
Peripheral thrombectomy, thrombolysis, and embolization overlap
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Penumbra | $319.09 | +0.10% | $12.56B | 78.3 | 57.6 | 8.3 | +14.9% |
| Stryker | $275.68 | +0.54% | $105.11B | 28.4 | 17.2 | 4.1 | +9.4% |
| Medtronic | $91.35 | −0.44% | $117.44B | 22.6 | 15.2 | 3.1 | +13.7% |
| Boston Scientific | $44.54 | +1.86% | $64.98B | 17.8 | 13.5 | 3.1 | +7.5% |
| Median | 22.6 | 15.2 | 3.1 | +9.4% |